Top-Rated StocksTop-RatedNASDAQ:INSM Insmed (INSM) Stock Price, News & Analysis $68.02 +0.49 (+0.73%) Closing price 04:00 PM EasternExtended Trading$67.94 -0.08 (-0.11%) As of 05:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Insmed Stock (NASDAQ:INSM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Insmed alerts:Sign Up Key Stats Today's Range$67.38▼$68.7450-Day Range$64.81▼$79.9252-Week Range$44.51▼$84.91Volume2.33 million shsAverage Volume2.33 million shsMarket Capitalization$12.39 billionP/E RatioN/ADividend YieldN/APrice Target$94.63Consensus RatingBuy Company OverviewInsmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.Read More… Insmed Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks86th Percentile Overall ScoreINSM MarketRank™: Insmed scored higher than 86% of companies evaluated by MarketBeat, and ranked 127th out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingInsmed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 17 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageInsmed has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Insmed's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Insmed are expected to grow in the coming year, from ($4.56) to ($2.89) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Insmed is -12.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Insmed is -12.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Insmed's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.66% of the outstanding shares of Insmed have been sold short.Short Interest Ratio / Days to CoverInsmed has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Insmed has recently increased by 4.37%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldInsmed does not currently pay a dividend.Dividend GrowthInsmed does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-1.58 Percentage of Shares Shorted8.66% of the outstanding shares of Insmed have been sold short.Short Interest Ratio / Days to CoverInsmed has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Insmed has recently increased by 4.37%, indicating that investor sentiment is decreasing. News and Social Media2.9 / 5News Sentiment1.27 News SentimentInsmed has a news sentiment score of 1.27. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 20 news articles for Insmed this week, compared to 12 articles on an average week.Search InterestOnly 2 people have searched for INSM on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Insmed to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Insmed insiders have sold 5,217.06% more of their company's stock than they have bought. Specifically, they have bought $201,694.00 in company stock and sold $10,724,192.00 in company stock.Percentage Held by InsidersOnly 3.00% of the stock of Insmed is held by insiders.Read more about Insmed's insider trading history. Receive INSM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Insmed and its competitors with MarketBeat's FREE daily newsletter. Email Address INSM Stock News HeadlinesInsider Buying: Insmed Incorporated (NASDAQ:INSM) Director Buys 1,130 Shares of StockMay 23, 2025 | insidertrades.comInsider Selling: Insmed Incorporated (NASDAQ:INSM) Insider Sells 1,799 Shares of StockMay 20, 2025 | insidertrades.comElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless production of electric vehicles and solar technology is driving demand for the precious metal to unprecedented levels. Silver—critical for EV batteries, solar panels, and advanced electronics—is now at the center of a supply crisis.May 27, 2025 | GoldenCrest Metals (Ad)Michael Alexander Smith Sells 409 Shares of Insmed Incorporated (NASDAQ:INSM) StockMay 16, 2025 | insidertrades.comWilliam Lewis Sells 6,830 Shares of Insmed Incorporated (NASDAQ:INSM) StockMay 3, 2025 | insidertrades.comTracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q1 2025 UpdateMay 27 at 12:39 AM | seekingalpha.comHow Do Investors Really Feel About Insmed?May 23, 2025 | benzinga.comBrensocatib Shows Consistent Efficacy and Safety Across Three Prespecified Subgroups in New Data from Landmark ASPEN StudyMay 21, 2025 | prnewswire.comSee More Headlines INSM Stock Analysis - Frequently Asked Questions How have INSM shares performed this year? Insmed's stock was trading at $69.04 at the beginning of 2025. Since then, INSM shares have decreased by 1.5% and is now trading at $68.02. View the best growth stocks for 2025 here. How were Insmed's earnings last quarter? Insmed Incorporated (NASDAQ:INSM) posted its quarterly earnings data on Thursday, May, 8th. The biopharmaceutical company reported ($1.42) EPS for the quarter, missing analysts' consensus estimates of ($1.36) by $0.06. Insmed's quarterly revenue was up 22.9% compared to the same quarter last year. Read the conference call transcript. Who are Insmed's major shareholders? Insmed's top institutional shareholders include Vanguard Group Inc. (10.05%), Price T Rowe Associates Inc. MD (7.11%), Adage Capital Partners GP L.L.C. (1.90%) and Alliancebernstein L.P. (1.33%). Insiders that own company stock include William Lewis, Melvin Md Sharoky, Roger Adsett, John Drayton Wise, Orlov S Nicole Schaeffer, Sara Bonstein, Michael Alexander Smith, Martina MD Flammer, Clarissa Desjardins and Clarissa Desjardins. View institutional ownership trends. How do I buy shares of Insmed? Shares of INSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Insmed own? Based on aggregate information from My MarketBeat watchlists, some other companies that Insmed investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), CrowdStrike (CRWD), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings5/08/2025Today5/27/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:INSM CIK1104506 Webwww.insmed.com Phone908-977-9900Fax732-438-0381Employees373Year FoundedN/APrice Target and Rating Average Stock Price Target$94.63 High Stock Price Target$109.00 Low Stock Price Target$63.00 Potential Upside/Downside+40.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)($5.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-749,570,000.00 Net Margins-251.24% Pretax Margin-251.01% Return on Equity-4,773.73% Return on Assets-54.58% Debt Debt-to-Equity Ratio2.03 Current Ratio6.37 Quick Ratio5.99 Sales & Book Value Annual Sales$381.03 million Price / Sales32.28 Cash FlowN/A Price / Cash FlowN/A Book Value($2.32) per share Price / Book-29.11Miscellaneous Outstanding Shares182,139,000Free Float170,673,000Market Cap$12.30 billion OptionableOptionable Beta0.84 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:INSM) was last updated on 5/27/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Insmed Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Insmed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.